Vaccines Market Research

Vaccines Market Research Reports & Industry Analysis

10 January 2020
Pharma
Vaccines Market Research

The global vaccine market is a steady grower, while also providing an absolutely vital medical service to billions of people around the world.  This makes the vaccines market a strong candidate for investment, as long as a company understands the risks involved.  This is what Visiongain specializes in.  We do in-depth vaccine market research, along with many other industries, to bring you the information needed to make strong decisions.

Our reports touch on many areas of the topic; here is a brief summary of the current state of the vaccine market research.

Vaccines Overview

Vaccines specifically formulated substances that improve human immunity to a variety of diseases.  Each vaccine is tailored to a specific disease, usually utilizing a dead or dormant form of that disease to train the body's immune system to fight it.  Currently, the primary market segmentations are for live attenuated vaccines, inactivated vaccines, and subunit/recombinant vaccines. 

Vaccines Market Global Outlook

On the whole, the vaccine market shows a growth rate of approximately 6.67% and is forecasted to remain there until the mid-2020s.   Of the various market segments, live attenuated vaccines (which use live, but harmless, disease matter) is by far the most dominant, accounting for the majority of vaccines in use.  The growth in this segment is projected to have a CAGR of 5.44% in the near future.

Of vaccines currently on the market, one strong growth area is in vaccines for the Human Papilloma Virus.  HPV is a mild sexually transmitted disease which is also linked to cervical cancer, and its vaccine being increasingly mandated by world governments.

As such, growth in the vaccine market is seen as largely government-driven.  States implement initiatives mandating vaccination, causing immediate boosts to the industry.  This fuels research into new vaccines, which are then introduced to the market.

Major Challenges to The Global Vaccine Market

Expansion into developing nations has been a continual challenge.  Many governments are at times disinterested in public health initiatives, or else lack the resources to implement widespread vaccination.  There is also a substantial lack of education among the public and some lingering distrust of vaccines themselves. These issues create uncertainty in the ability of the market to grow globally.

In addition, the production of new vaccines is extremely expensive, with long and arduous regulations that must be cleared, slowing the introduction of new products.

Visiongain has far more insights to share.  Click here to browse our selection of pharmaceutical market research.

Recent News

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

Read

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

Read

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever